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BACKGROUND
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease character-
ized by chronic complement-mediated hemolysis. C5 inhibition controls intravas-
cular hemolysis in untreated PNH but cannot address extravascular hemolysis. 
Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, 
potentially inhibits both intravascular and extravascular hemolysis.
METHODS
We conducted a phase 3 open-label, controlled trial to assess the efficacy and 
safety of pegcetacoplan as compared with eculizumab in adults with PNH and 
hemoglobin levels lower than 10.5 g per deciliter despite eculizumab therapy. After 
a 4-week run-in phase in which all patients received pegcetacoplan plus eculizu-
mab, we randomly assigned patients to subcutaneous pegcetacoplan monotherapy 
(41 patients) or intravenous eculizumab (39 patients). The primary end point was 
the mean change in hemoglobin level from baseline to week 16. Additional clinical 
and hematologic markers of hemolysis and safety were assessed.
RESULTS
Pegcetacoplan was superior to eculizumab with respect to the change in hemoglo-
bin level from baseline to week 16, with an adjusted (least squares) mean differ-
ence of 3.84 g per deciliter (P<0.001). A total of 35 patients (85%) receiving pegce-
tacoplan as compared with 6 patients (15%) receiving eculizumab no longer 
required transfusions. Noninferiority of pegcetacoplan to eculizumab was shown 
for the change in absolute reticulocyte count but not for the change in lactate 
dehydrogenase level. Functional Assessment of Chronic Illness Therapy–Fatigue 
scores improved from baseline in the pegcetacoplan group. The most common 
adverse events that occurred during treatment in the pegcetacoplan and eculizu-
mab groups were injection site reactions (37% vs. 3%), diarrhea (22% vs. 3%), 
breakthrough hemolysis (10% vs. 23%), headache (7% vs. 23%), and fatigue (5% 
vs. 15%). There were no cases of meningitis in either group.
CONCLUSIONS
Pegcetacoplan was superior to eculizumab in improving hemoglobin and clinical 
and hematologic outcomes in patients with PNH by providing broad hemolysis 
control, including control of intravascular and extravascular hemolysis. (Funded by 
Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.)
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Paroxysmal nocturnal hemoglobin-uria (PNH) is a rare, acquired, clonal, non-malignant hematologic disease character-
ized by complement-mediated hemolysis (with 
or without hemoglobinuria), fatigue, increased 
susceptibility to thrombosis, and some degree of 
bone marrow dysfunction.1 PNH results from 
the expansion of abnormal hematopoietic clones 
that lack cell-surface complement inhibitory pro-
teins attached to the membrane through glyco-
sylphosphatidylinositol anchors.2-5 At least two 
of the missing glycosylphosphatidylinositol-linked 
proteins, CD55 and CD59, are key regulators of 
the complement pathway and protect host cells 
from complement-mediated removal.6-8 This com-
plement dysregulation leads to chronic hemoly-
sis and thrombosis characteristic of PNH.1,9 
Manifestations of hemolysis are due directly to 
the increased sensitivity of PNH cells to com-
plement.5,10
Intravascular hemolysis of CD59-deficient 
erythrocytes results in the hemoglobinuria after 
which PNH is named.6,11 The development of 
targeted terminal complement C5 inhibitors has 
transformed outcomes for patients with PNH by 
controlling intravascular hemolysis. In addition, 
C5 inhibitors prevent terminal complement-
mediated platelet and white-cell activation and 
destruction, thereby leading to a marked reduc-
tion in thrombosis, which is the main life-
threatening complication of PNH.12,13 C5 inhibi-
tion also ameliorates anemia and reduces the 
need for transfusions and prevents many PNH 
complications such as kidney failure and pulmo-
nary hypertension.12,14,15
PNH erythrocytes also lack CD55, leading to 
reduction in C3-convertase enzyme dissociation, 
increase in the production of C3 fragments, and 
subsequent opsonization.7 Although eculizumab 
is effective in preventing C5-dependent intra-
vascular hemolysis mediated by the membrane-
attack complex, surviving PNH erythrocytes be-
come opsonized with C3 fragments and are 
removed by extravascular hemolysis in the liver 
and spleen.16 Extravascular hemolysis is observed 
in most patients with PNH who are being treat-
ed with C5 inhibitors and leads to reduced 
erythrocyte half-life (10 to 13 days).16,17 Extravas-
cular hemolysis can manifest as persistent ane-
mia despite C5 inhibitor treatment and may 
contribute to the need for continued blood 
transfusions.16-19
Pegcetacoplan is a pegylated pentadecapep-
tide that targets complement C320 to control both 
intravascular and extravascular hemolysis. The 
PEGASUS trial is a 48-week, phase 3, random-
ized, multicenter, open-label, active-comparator–
controlled trial of the efficacy and safety of 
pegcetacoplan as compared with eculizumab in 
patients with PNH and a hemoglobin level of 
less than 10.5 g per deciliter despite treatment 
with eculizumab. We report here the primary 




Adult patients (≥18 years of age) in whom PNH 
was diagnosed by high-sensitivity flow cytome-
try and who had hemoglobin levels of less than 
10.5 g per deciliter while they were receiving 
stable doses of eculizumab for at least 3 months 
before screening were eligible for participation 
in the trial. Additional information about eligibil-
ity criteria, end points, and statistical analyses is 
provided in the Methods section of the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org. All patients provided 
written informed consent before enrollment.
Trial Design
The trial was conducted in accordance with 
Good Clinical Practice guidelines and the prin-
ciples of the Declaration of Helsinki, and the 
protocol (available at NEJM.org) was approved by 
the relevant institutional review board or ethics 
committee at each site. The trial was designed 
by the sponsor (Apellis Pharmaceuticals) and the 
academic authors. The sponsor conducted trial 
oversight and provided the pegcetacoplan; ecu-
lizumab was provided to sites where it was not 
part of the standard of care. Trial investigators 
collected the data, which were analyzed by the 
sponsor. The first author and senior industry 
author wrote the first draft of the manuscript; 
medical writing assistance was paid for by the 
sponsor. The authors vouch for the completeness 
and accuracy of the data and for the fidelity of 
the trial to the protocol. The sponsor reviewed 
and provided feedback on the manuscript. Full 
editorial control of the manuscript was main-
tained by the authors, all of whom provided 
their final approval of the manuscript submitted 
for publication. Confidentiality agreements were 
in place between all the authors and the sponsor.
A Quick Take is  
available at  
NEJM.org 
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The trial treatment period consisted of three 
parts (Fig. 1). During a 4-week run-in phase, all 
the patients continued to receive their current 
dose of eculizumab with the addition of twice-
weekly pegcetacoplan (1080 mg), which the pa-
tients administered themselves subcutaneously. 
After the run-in phase, patients were randomly 
assigned, in a 1:1 ratio, to monotherapy with 
pegcetacoplan or eculizumab for 16 weeks (ran-
domized, controlled period). This period was 
followed by a 32-week period in which all patients 
received open-label pegcetacoplan. Randomiza-
tion was stratified according to the number of 
packed red-cell transfusions patients had re-
ceived during the 12 months before screening 
(<4 or ≥4) and the platelet count at screening 
(<100,000 or ≥100,000 cells × 109 per liter).
Clinical Efficacy
The primary end point was the change in hemo-
globin level from baseline to week 16 during the 
randomized, controlled period. Key secondary 
end points were the proportion of patients who 
did not require a transfusion during the ran-
domized, controlled period and the change from 
baseline to week 16 in absolute reticulocyte 
count, lactate dehydrogenase (LDH) level, and 
score on the Functional Assessment of Chronic 
Illness Therapy–Fatigue (FACIT-F) scale (scores 
range from 0 to 52, with higher scores indicat-
ing less fatigue). Additional end points are de-
scribed in the Supplementary Appendix.
Safety
Safety end points included the incidence and 
severity of adverse events that occurred during 
the run-in phase or beyond, the incidence of 
thromboembolic events, and the changes from 
baseline in laboratory and electrocardiographic 
variables.
Statistical Analysis
The between-group comparison for the primary 
end point was performed with the use of a 
mixed-effect model for repeated measures 
(MMRM), with baseline hemoglobin as a con-
tinuous variable, time point as a categorical vari-
able, and treatment group, stratification vari-
ables, and time-by-treatment interaction as fixed 
effects. Transfusions were considered to be inter-
current events that could confound the results, 
and data after the first transfusion were cen-
sored. To control for a type 1 error, the key 
secondary end points were tested for noninferi-
ority in the following hierarchical manner if 
superiority was declared for the primary end 
point: the proportion of patients who did not 
require a transfusion during the randomized, 
controlled period, followed by change from 
baseline to week 16 in absolute reticulocyte 
count, LDH level, and FACIT–F score. Analyses 
were also conducted with all observed data con-
sidered (with no censoring of post-transfusion 
data). Additional details are shown in the Meth-
ods section of the Supplementary Appendix.
Figure 1. Trial Design.
The trial treatment period consisted of three parts: a 4‑week run‑in period, followed by a 16‑week randomized, controlled period during 
which patients received either pegcetacoplan or eculizumab as monotherapy, and a 32‑week open‑label period during which patients 
 received pegcetacoplan. Patients who received eculizumab during the 16‑week randomized, controlled period continued to receive ecu‑
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R esult s
Patients
Of 102 patients screened, 80 (49 women and 31 
men) met the entry criteria and were enrolled 
across 44 centers; 41 patients were randomly as-
signed to receive pegcetacoplan and 39 to receive 
eculizumab during the 16-week randomized, 
controlled period (Fig. S1 in the Supplementary 
Appendix). All 39 patients assigned to receive 
eculizumab completed the 16 weeks of therapy; 
3 of the 41 patients in the pegcetacoplan group 
discontinued therapy before week 16 owing to 
breakthrough hemolysis. The trial was conduct-
ed from June 2018 through November 2019.
Demographic and baseline characteristics 
were generally balanced between the two groups 
(Table 1). The mean time from diagnosis of PNH 
to the first day of the 4-week run-in phase was 
10.18 years overall and was longer in the eculizu-
mab group than in the pegcetacoplan group 
(11.68 years vs. 8.74 years), although this differ-
ence was not statistically significant. The dura-
tion of previous eculizumab treatment was 
similar in the two groups. In the overall trial 
population, 25 patients (31%) had a history of 
thrombosis and 20 (25%) had a history of aplas-
tic anemia. Twenty-four patients (30%) were re-
ceiving eculizumab doses higher than 900 mg 




Pegcetacoplan was superior to eculizumab with 
respect to the change in hemoglobin level from 
baseline to week 16 (Fig. 2). The adjusted (least 
squares) mean change from baseline was 2.37 g 
per deciliter with pegcetacoplan and –1.47 g per 
deciliter with eculizumab, for a mean difference 
between treatments of 3.84 g per deciliter (95% 
confidence interval [CI], 2.33 to 5.34; P<0.001) 
at week 16 (Fig. 2B). The results of a supportive 
analysis of the primary end point that included 
all available data (not censored for transfusions) 
were consistent with the results of the primary 
analysis; the adjusted mean change from base-
line to week 16 with inclusion of all available 
data was 2.66 g per deciliter with pegcetacoplan 
and −0.03 g per deciliter with eculizumab, for 
a mean difference between treatments of 2.69 g 
per deciliter (95% CI, 1.99 to 3.38; P<0.001).
Increased hemoglobin levels in patients re-
ceiving pegcetacoplan monotherapy, as compared 
with patients receiving eculizumab monotherapy, 
were seen as early as week 2 of the 16-week 
randomized, controlled period and were main-
tained throughout the 16-week period (Fig. 2A). 
In a subgroup analysis according to pretrial trans-
fusion requirements, improvements from base-
line in hemoglobin level in the pegcetacoplan 
group (2.97 g per deciliter among patients with 
<4 transfusions in the 12 months before screen-
ing and 2.11 g per deciliter among patients with 
≥4 transfusions) were consistent with the im-
provements in the overall cohort; however, in 
the eculizumab group, patients with fewer than 
4 transfusions in the 12 months before screen-
ing had a decrease in hemoglobin of 0.01 g per 
deciliter, and patients with 4 or more transfu-
sions in the 12 months before screening had a 
decrease in hemoglobin of 4.02 g per deciliter 
(Fig. 2B). When all observed data were consid-
ered, the results of all primary and key second-
ary analyses were consistent with the MMRM 
analyses in which post-transfusion data were 
censored.
Key Secondary End Points
Over the 16-week randomized, controlled period, 
35 patients (85%) in the pegcetacoplan group 
were transfusion-free, whereas only 6 (15%) in 
the eculizumab group were transfusion-free 
(P<0.001) (Fig. 3). Consistent effects regarding 
freedom from transfusion were seen regardless 
of the transfusion stratum in the 12 months 
before trial initiation (Table S1).
The absolute reticulocyte count decreased 
with pegcetacoplan and slightly increased with 
eculizumab (adjusted mean [±SE] changes, 
−136±7 × 109 per liter and 28±12 × 109 per liter, 
respectively), a finding that showed the noninfe-
riority of pegcetacoplan to eculizumab (Fig. 3 
and Fig. S2A). Noninferiority was not shown for 
the change from baseline in LDH level (Fig. 3); 
the adjusted mean change from baseline was 
−15±43 U per liter in the pegcetacoplan group 
and −10±71 U per liter in the eculizumab group. 
Additional information is provided in the Sup-
plementary Appendix.
FACIT–F scores increased with pegcetacoplan 
by 9.2 points and decreased with eculizumab by 
2.7 points (Fig. S2C), resulting in an adjusted 
mean difference of 11.9 points (95% CI, 5.49 to 
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18.25) at week 16 (Fig. 3). This difference was 
considered to be clinically significant, but non-
inferiority was not assessed because of the pre-
specified statistical hierarchical testing rules. 
Furthermore, 73% of patients in the pegcetaco-
plan group had at least a 3-point increase in 
FACIT–F scores at week 16, as compared with 
0% in the eculizumab group; a 3-point change is 
considered clinically significant.
A greater percentage of patients in the peg-
cetacoplan group than in the eculizumab group 
had normalization of key hematologic variables 
— hemoglobin level (34% vs. 0%), reticulocyte 
count (78% vs. 3%), LDH level (71% vs. 15%), 
and total bilirubin level (63% vs. 8%). (Addi-
tional information on FACIT–F scores and hema-
tologic variables is available in Table S2.)
Safety
Adverse events that occurred during treatment 
were recorded in 36 patients (88%) receiving 
pegcetacoplan and in 34 (87%) receiving ecu-
Table 1. Demographic and Clinical Characteristics of Patients at Baseline.*
Characteristic Pegcetacoplan (N = 41) Eculizumab (N = 39)
Age
Mean (range) — yr 50.2 (19–81) 47.3 (23–78)
>65 yr — no. (%) 10 (24) 7 (18)
Female sex — no. (%) 27 (66) 22 (56)
Race — no. (%)†
Asian 5 (12) 7 (18)
Black 2 (5) 0
White 24 (59) 25 (64)
Other 0 1 (3)
Not reported 10 (24) 6 (15)
Body‑mass index‡ 26.7±4.3 25.9±4.3
No transfusions within previous 12 mo — no. (%) 10 (24) 10 (26)
History of aplastic anemia — no. (%) 11 (27) 9 (23)
Median time since PNH diagnosis (range) — yr 6.0 (1–31) 9.7 (1–38)
Median duration of prior treatment with eculizumab (range) — yr 4.4 (0.4–17.1) 3.4 (0.3–13.8)
Eculizumab dose at screening — no. (%)
900 mg every 2 wk 26 (63) 30 (77)
1200 mg every 2 wk§ 13 (32) 9 (23)
1500 mg every 2 wk 2 (5) 0
Platelets — ×10−9/liter 166.6±98.3 146.9±68.8
≥4 transfusions in previous 12 mo — no. (%) 21 (51) 23 (59)
Hemoglobin — g/dl¶ 8.69±1.08 8.68±0.89
Reticulocyte count — ×10−9/liter (normal reference range) 217.5±75.0 (30–120) 216.2±69.1 (30–120)
Lactate dehydrogenase — U/liter (normal reference range) 257.5±97.6 (113–226) 308.6±284.8 (113–226)
Total bilirubin — μmol/liter (normal reference range) 42.5±31.5 (1.7–18.8) 40.5±26.6 (1.7–18.8)
Indirect bilirubin — μmol/liter 34.7±28.5 32.9±23.0
FACIT–F score‖ 32.2±11.4 31.6±12.5
*  Plus–minus values are means ±SD. PNH denotes paroxysmal nocturnal hemoglobinuria.
†  Race and ethnic group were reported by the patient.
‡  The body‑mass index is the weight in kilograms divided by the square of the height in meters.
§  One patient in the pegcetacoplan group received 900 mg of eculizumab every 11 days.
¶  The normal reference range for women is 12 to 16 and for men is 13.6 to 18.
‖  Scores on the Functional Assessment of Chronic Illness Therapy‑Fatigue (FACIT–F) scale range from 0 to 52, with 
higher scores indicating less fatigue.
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lizumab (Table 2). The most common adverse 
events in the pegcetacoplan and eculizumab 
groups were injection-site reactions (37% vs. 
3%), diarrhea (22% vs. 3%), breakthrough hemo-
lysis (10% vs. 23%), headache (7% vs. 23%), and 
fatigue (5% vs. 15%). The majority of injection-
site reactions were mild and occurred early in 
the trial; none resulted in discontinuation. Diar-
rhea events were mostly mild single episodes. 
The incidence of serious adverse events was also 
similar in the two groups, with events reported 
in 7 patients (17%) receiving pegcetacoplan and 
in 6 (15%) receiving eculizumab (Table 2).
Infections were reported in 12 patients (29%) 
in the pegcetacoplan group and in 10 (26%) in 
the eculizumab group (Table 2). Meningitis was 
not reported in either treatment group. One case 
of sepsis was reported during the run-in period 
and was considered by the principal investigator 
to be unrelated to the initiation of pegcetaco-
plan treatment. No patient had a thrombotic 
event, and no deaths occurred during the trial.
Breakthrough hemolysis was reported in 4 
patients (10%) receiving pegcetacoplan and in 9 
(23%) receiving eculizumab. All four pegcetaco-
plan-treated patients who had breakthrough 
hemolysis had an elevation of LDH level to more 
than 3 times the upper limit of the normal 
range. The breakthrough hemolysis was associ-
ated with a rapid increase in LDH level indicat-
ing intravascular hemolysis, occurred without 
identifiable triggers or detectable anti-pegceta-
Figure 2. Hemoglobin Levels from Baseline to Week 16.
Panel A shows adjusted mean hemoglobin levels from baseline to week 16 and includes all the available data for all 
patients, regardless of transfusion events. Week 8 data include three patients in the pegcetacoplan group who had 
discontinued the trial and one patient with missing data. The dashed line indicates the lower limit of the normal 
range for female patients. I bars indicate standard errors. Panel B shows the primary end point, the adjusted change 
in least‑squares (LS) mean (±SE) hemoglobin level from baseline to week 16, for the total patient population (both 
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coplan antibodies, and resulted in three patients 
discontinuing treatment with pegcetacoplan and 
switching back to treatment with eculizumab. 
One patient had a hemolysis event with a maxi-
mum severity of “severe” on trial days 47 through 
53, one patient had a moderate hemolysis event 
on trial days 49 through 56, and one patient had 
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through 39. All 39 patients in the eculizumab 
group crossed over to the open-label pegcetaco-
plan monotherapy group for a 4-week run-in 
period during which they received eculizumab 
and pegcetacoplan, followed by 28 weeks of 
monotherapy (full patient data are provided in 
the Supplementary Appendix and Table S4).
Discussion
The primary finding of this trial is that pegceta-
coplan treatment, which targets C3, was associ-
ated with a significantly greater increase in 
hemoglobin level than that observed in patients 
treated with the C5 inhibitor eculizumab. De-
spite treatment with eculizumab for an average 
of 5 years, with 30% receiving doses that were 
higher than the doses approved for PNH, the 
trial population remained severely anemic (mean 
baseline hemoglobin level, 8.7 g per deciliter), 
continued to be transfusion-dependent (with 
75% requiring at least one transfusion during 
the previous year), and reported considerable 
fatigue, with a mean baseline FACIT–F score of 
32 (with a score of 43.6 considered normal for a 
healthy adult).21 In addition to the increase in 
hemoglobin level, more than one third of the 
patients treated with pegcetacoplan showed nor-
malized levels of hemoglobin at week 16 and 
most (85%) did so without receiving a transfu-
sion, whereas only 15% in the eculizumab group 
were transfusion-free during the 16-week random-
ized period. Furthermore, the effect on freedom 
Figure 3 (facing page). Changes in Primary and Key  
Secondary Efficacy End Points from Baseline to Week 16.
Shown are data on the primary (Panel A) and key second‑
ary (Panels B through E) efficacy end points. Adjusted 
least‑squares (LS) means (±SE) were calculated with the 
use of mixed‑model repeated measures analysis. The dif‑
ferences are adjusted for stratification variables. Key sec‑
ondary end‑point analyses were based on prespecified 
noninferiority margins. Noninferiority was achieved if the 
lower or upper limit of the 95% confidence interval of the 
treatment difference met the prespecified margin. Key 
secondary end points were tested in a hierarchical man‑
ner for noninferiority if superiority was declared for the 
primary end point. Scores on the Functional Assessment 
of Chronic Illness Therapy–Fatigue (FACIT‑F; scores range 
from 0 to 52, with higher scores indicating less fatigue) 
were not tested for noninferiority because the between‑
group difference in lactate dehydrogenase (LDH) level 
did not meet the noninferiority criterion. No further 
end points were tested. CI denotes confidence interval.







no. of patients (%)
Any adverse event occurring during treatment 36 (88) 34 (87)
Adverse event in >5% of patients in either 
group
Injection‑site erythema 7 (17) 0
Injection‑site reaction 5 (12) 0
Injection‑site swelling 4 (10) 0
Asthenia 3 (7) 3 (8)
Injection‑site induration 3 (7) 0
Fatigue 2 (5) 6 (15)
Pyrexia 2 (5) 2 (5)
Vaccination‑site pain from any vaccine* 0 2 (5)
Back pain 3 (7) 4 (10)
Pain in arms or legs 3 (7) 1 (3)
Diarrhea 9 (22) 1 (3)
Abdominal pain 5 (12) 4 (10)
Nausea 2 (5) 2 (5)
Vomiting 0 3 (8)
Viral upper respiratory tract infection 2 (5) 2 (5)
Hemolysis 4 (10) 9 (23)
Anemia 0 5 (13)
Headache 3 (7) 9 (23)
Dizziness 1 (2) 4 (10)
Hypertension 3 (7) 1 (3)
Dyspnea 1 (2) 2 (5)
Oropharyngeal pain 0 2 (5)
Hyperbilirubinemia 0 2 (5)
Anxiety 1 (2) 2 (5)
Insomnia 0 2 (5)
Palpitations 0 2 (5)
Chromaturia 0 2 (5)
Serious adverse events occurring during 
 treatment
Any 7 (17) 6 (15)
Occurring in >1 patient in the pegcetaco‑
plan group
Hemolysis 2 (5) 1 (3)
*  Patients were required to receive vaccinations against Neisseria meningitides 
types A, C, W, Y, and B, Streptococcus pneumoniae, and Haemophilus influen-
zae type B within 2 years before receiving the first dose of pegcetacoplan or 
within 14 days after the first dose.
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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
from transfusion was consistent regardless of 
the transfusion burden during the previous year.
Markers of extravascular hemolysis such as 
reticulocytosis and hyperbilirubinemia were nor-
malized in most patients in the pegcetacoplan 
group at week 16. Markers of intravascular he-
molysis, notably LDH level, were relatively well 
controlled at baseline, as expected with treat-
ment with a C5 complement inhibitor, and re-
mained well controlled at week 16 in both treat-
ment groups. These results show that inhibition 
of complement C3 was adequate to maintain con-
trol of intravascular hemolysis and also prevent 
extravascular hemolysis. Our data show that 71% 
of patients receiving pegcetacoplan had normal-
ization of LDH levels at week 16, as compared 
with 15% of patients receiving eculizumab. Of 
note, reduction of mean LDH level to within the 
normal range was seen by the end of the run-in 
period and was maintained in patients receiving 
pegcetacoplan throughout the randomized, con-
trolled period.
The effect of improvements in hemoglobin 
levels and control of underlying hemolysis trans-
lates not only to clinical variables such as free-
dom from transfusion but also to improvements 
in patient-reported outcomes. Fatigue is the most 
commonly reported symptom in patients with 
PNH and can have a tremendous adverse effect 
on quality of life.22 Patients receiving pegcetaco-
plan had an improvement of 11.9 points on the 
FACIT–F scale (an increase of >3 points is gener-
ally considered clinically meaningful in other 
disease states). These improvements and differ-
ences between pegcetacoplan and eculizumab 
were evident irrespective of whether data after 
transfusions were included in analyses (Fig. S2); 
however, the open-label trial design does not ex-
clude the potential for bias, and these improve-
ments must be interpreted carefully.
A potential concern with broad complement 
inhibition is the possibility of increased risk of 
encapsulated bacterial infections.23,24 The inhibi-
tion of the terminal complement leads to a well-
defined risk of neisseria infection.25 In the 
PEGASUS trial, no cases of meningococcal in-
fection were noted in either group, and no dif-
ference in the incidence of infections was dis-
cerned between the two groups, with 29% and 
26% of patients in the pegcetacoplan and eculizu-
mab groups, respectively, reporting infections. 
Although these findings are encouraging, longer-
term data on the incidence of infection with 
proximal complement inhibition are needed. 
Overall, safety and the side-effect profile were 
similar in the pegcetacoplan and eculizumab 
groups. As expected with the introduction of 
patients to frequent subcutaneous infusions that 
they administered themselves, injection-site re-
actions were the most common adverse events 
reported by patients in the pegcetacoplan group, 
but most events were mild, occurred early in the 
trial, and did not lead to any discontinuations.
Breakthrough hemolysis was reported more 
often in patients who received eculizumab than 
in those who received pegcetacoplan; however, 
three patients discontinued treatment with peg-
cetacoplan owing to a recurrence of intravascu-
lar hemolysis. Pharmacokinetic factors or under-
lying disease severity (details provided in the 
Supplementary Appendix) may have played a role 
and suggest that a small subgroup of patients 
may require dose adjustments of pegcetacoplan 
after cessation of eculizumab; this warrants 
further study. Lack of adherence to the trial drug 
was not observed in the three patients who dis-
continued pegcetacoplan.
Clinical data from the three patients who 
discontinued the trial were not collected after 
the time these patients stopped treatment with 
pegcetacoplan, and this may have had some ef-
fect on the differences observed between the 
treatment groups after the point of discontinua-
tion. However, the extent of the effect would be 
difficult to assess, and data from these three 
patients before they stopped treatment with 
pegcetacoplan are included in the primary MMRM 
analysis.
The PEGASUS trial showed that in patients with 
persistent anemia despite eculizumab therapy, the 
C3 inhibitor pegcetacoplan was superior to the C5 
inhibitor eculizumab with respect to the change 
from baseline to week 16 in hemoglobin level 
and provided improvements in key hematologic 
and clinical variables, such as freedom from trans-
fusion. Adverse effects included mainly injection-
site irritation and mild diarrhea. In this popula-
tion, treating intravascular hemolysis as well as 
preventing extravascular hemolysis by proximal 
complement inhibition with pegcetacoplan may 
result in better control of disease than treatment 
with eculizumab.
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